Endurant Capital Management LP Aclaris Therapeutics, Inc. Transaction History

Endurant Capital Management LP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.64 - $6.49 $94,976 - $963,116	148,400 New	148,400 $155,000
Q1 2023 May 15, 2023	BUY	$7.07 - $17.95 $593,109 - $1.51 Million	83,891 New	83,891 $678,000
Q4 2021 Feb 14, 2022	SELL	$12.27 - $18.49 $825,771 - $1.24 Million	-67,300 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$13.38 - $18.8 $696,803 - $979,066	-52,078 Reduced 43.62%	67,300 $1.21 Million
Q2 2021 Aug 16, 2021	SELL	$17.08 - $29.6 $5.74 Million - $9.95 Million	-336,007 Reduced 73.79%	119,378 $2.1 Million
Q1 2021 May 17, 2021	SELL	$5.86 - $27.73 $3.93 Million - $18.6 Million	-671,290 Reduced 59.58%	455,385 $11.5 Million
Q4 2020 Feb 16, 2021	SELL	$2.65 - $7.61 $811,276 - $2.33 Million	-306,142 Reduced 21.37%	1,126,675 $7.29 Million
Q3 2020 Nov 16, 2020	SELL	$1.5 - $2.71 $443,955 - $802,078	-295,970 Reduced 17.12%	1,432,817 $3.68 Million
Q2 2020 Aug 14, 2020	SELL	$1.04 - $1.73 $926,016 - $1.54 Million	-890,400 Reduced 34.0%	1,728,787 $2.8 Million
Q1 2020 May 15, 2020	BUY	$0.75 - $2.18 $423,088 - $1.23 Million	564,118 Added 27.45%	2,619,187 $2.72 Million
Q4 2019 Feb 14, 2020	BUY	$1.02 - $1.97 $290,989 - $562,009	285,284 Added 16.12%	2,055,069 $3.88 Million
Q3 2019 Nov 14, 2019	BUY	$0.79 - $2.47 $110,961 - $346,931	140,458 Added 8.62%	1,769,785 $1.91 Million
Q2 2019 Aug 14, 2019	BUY	$2.13 - $7.06 $2.31 Million - $7.65 Million	1,083,598 Added 198.56%	1,629,327 $3.57 Million
Q1 2019 May 15, 2019	BUY	$5.63 - $7.84 $3.07 Million - $4.28 Million	545,729 New	545,729 $3.27 Million

50.7M

30.6K

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $255M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.